Compare · DOMH vs NVO
DOMH vs NVO
Side-by-side comparison of Dominari Holdings Inc. (DOMH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DOMH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 3569.9x DOMH ($62.4M).
- Over the past year, DOMH is down 48.6% and NVO is down 21.8% - NVO leads by 26.8 points.
- DOMH has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for DOMH).
- Company
- Dominari Holdings Inc.
- Novo Nordisk A/S
- Price
- $2.76-1.78%
- $50.31-2.25%
- Market cap
- $62.4M
- $222.81B
- 1M return
- -14.29%
- +15.47%
- 1Y return
- -48.56%
- -21.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DOMH
- SEC Form 4 filed by Director Parsley Brian Keith
- SEC Form 4 filed by Director Blattner Gregory James
- SEC Form 4 filed by Chief Financial Officer Ledwick Tim S
- SEC Form 4 filed by COO Devall Christopher Franklin
- SEC Form 4 filed by Director Haug Kyle
- Dominari Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Dominari Securities Raises $200,000,000.00 in World's Largest IPO
- The Rise of the American Drone Industry
- Dominari Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S